BioPharmSignal logoBioPharmSignal

Biotech News

ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update

ADMA Biologics (ADMA)ADMA BiologicsEarnings

1Q 2026 Total Revenue of $114.5 Million, Flat Year-Over-Year 1Q 2026 ASCENIV Revenue +28% Year-Over-Year; BIVIGAM Revenue -54% Year-Over-Year 1Q 2026 Adjusted Net Income ( 1) of $40.7 Million, 22% Year-Over-Year Growth 1Q 2026 Adjusted EBITDA ( 2) of $59.7 Million, Representing 24% Year-Over-Year

Related news

ADMAADMA Biologics2026-08-05 20:05 EST

ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update

ADMAADMA Biologics2026-04-29 11:00 EST

ADMA Biologics to Report First Quarter 2026 Financial Results on May 6, 2026

CHRSCoherus BioSciences, Inc.2026-05-11 20:05 EST

Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update

STTKShattuck Labs2025-05-01 20:20 EST

Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights

CHRSCoherus BioSciences, Inc.2026-08-05 20:28 EST

Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update

APGEApogee Therapeutics2026-05-11 11:00 EST

Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results

ENTXEntera Bio2026-05-08 20:05 EST

Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs

STTKShattuck Labs2026-05-07 10:15 EST

Shattuck Labs Reports First Quarter 2026 Financial Results and Recent Business Highlights

RXRXRecursion2026-05-06 10:30 EST

Recursion Reports First Quarter Financial Results and Provides Business Update

MDXGMiMedx2026-04-29 20:01 EST

MIMEDX Announces First Quarter 2026 Operating & Financial Results

View all latest news

ADMA Biologics

Plasma-Derived Biologics ADMA Biologics is a vertically integrated U.S. manufacturer and marketer of plasma-derived immunoglobulin therapies for immunodeficient patients and people at risk of infection. ASCENIV ASCENIV is an intravenous immunoglobulin enriched with antibodies against respiratory syncytial virus. It is positioned for...

Recent company news

ADMAADMA Biologics2026-08-05 20:05 EST

ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update

ADMAADMA Biologics2026-07-29 11:00 EST

ADMA Biologics to Report Second Quarter 2026 Financial Results on August 5, 2026

ADMAADMA Biologics2026-05-06 20:05 EST

ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update

ADMAADMA Biologics2026-05-04 11:00 EST

ADMA Biologics Announces FDA Approval to Expand the Label for ASCENIV™ to Include Pediatric Immune Compromised Patients Two Years of Age and Older

ADMAADMA Biologics2026-04-29 11:00 EST

ADMA Biologics to Report First Quarter 2026 Financial Results on May 6, 2026

Stock data

Close
10.06 USD
Market cap
1.76B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States